This webcast provides a comprehensive update on finerenone, a non-steroidal mineralocorticoid receptor antagonist (nsMRA), and its role in chronic kidney disease (CKD), type 2 diabetes (T2D) as leading cause of CKD and heart failure (HF). The programme reviews the high burden of CKD and its close links with cardiovascular disease, explains how mineralocorticoid receptor overactivation drives inflammation and fibrosis, and highlights the clinical evidence from large outcome trials with finerenone. In addition, it examines its role in HF management and discusses the complementary benefits of combining nsMRAs with SGLT2 inhibitors as part of a modern cardiorenal treatment strategy, offering practical insights to support evidence-based care and improved patient outcomes.